(Q38759279)

English

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models

scientific article published on 7 July 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

based on heuristic

inferred from title

L'Houcine Ouafik

12

object named as

L'Houcine Ouafik

0 references

Esteban Cvitkovic

5

object named as

Esteban Cvitkovic

0 references

Lucile Astorgues-Xerri

2

object named as

Lucile Astorgues-Xerri

0 references

François Lokiec

10

object named as

François Lokiec

0 references

author name string

Caroline Berenguer-Daizé

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lucile Astorgues-Xerri

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Elodie Odore

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Mylène Cayol

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Esteban Cvitkovic

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Kay Noel

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Mohamed Bekradda

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sarah MacKenzie

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Keyvan Rezai

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

François Lokiec

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Maria E Riveiro

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

7 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

2047-2055

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Pathology of gliomas and developments in molecular testing

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Developing epigenetic diagnostics and therapeutics for brain disorders

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

BET domain co-regulators in obesity, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Bromodomains as therapeutic targets

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

BET bromodomain proteins are required for glioblastoma cell proliferation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Inhibition of BET bromodomain targets genetically diverse glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Selective inhibition of BET bromodomains

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Targeting MYC dependence in cancer by inhibiting BET bromodomains

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Selective inhibition of tumor oncogenes by disruption of super-enhancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Small-molecule inhibition of BRDT for male contraception

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30256

21 January 2018

Identifiers

10.1002/IJC.30256

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38759279&oldid=1783077084"